One of the clarified mechanisms for the increased sensitivity of lung cancer cells to platinum agents by PARP inhibition is based on synthetic lethality effects produced by the simultaneous impairment of PARP1 and PARP2, which is involved in base excision repair, with dysfunction of genes associated with DNA damage response such as homologous recombination (HR). The gene discussed is PARP1; the disease is lung carcinoma.